Bulwark Capital’s Novavax NVAX Stock Holding History

Bulwark Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-610	Closed	-$5.75K	–	110
2026 Q2	$5.75K	Hold	610	–	–	﹤0.01%	97
2026 Q1	$4.96K	Hold	610	–	–	﹤0.01%	93
2025 Q4	$4.1K	Hold	610	–	–	﹤0.01%	90
2025 Q3	$5.29K	Hold	610	–	–	﹤0.01%	94
2025 Q2	$3.84K	Buy	+610	New	+$4.04K	﹤0.01%	88

Other funds holding NVAX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return

Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Bulwark Capital's NVAX Position: Q3 2026 in Review

Bulwark Capital sold out of Novavax (NVAX) in Q3 2026, closing a stake of 610 shares — an estimated $5.75K sold.

Bulwark Capital first reported a position in NVAX in Q2 2025 and held it in 5 quarters. The position peaked at $5.75K in Q2 2026. 195 funds tracked by Wall St. Rank hold NVAX as of Q3 2026.

Bulwark Capital reported no remaining Novavax position as of Q3 2026 after selling out during the quarter.
Bulwark Capital sold 610 Novavax shares in Q3 2026, an estimated $5.75K.
Bulwark Capital first reported a position in Novavax in Q2 2025 and held it in 5 quarters.
Bulwark Capital's Novavax position peaked at $5.75K in Q2 2026.
195 funds tracked by Wall St. Rank held Novavax as of Q3 2026.

Based on Bulwark Capital's 13F filing for Q3 2026, filed 13 Oct 2026.